Comments
Loading...

ARS Pharmaceuticals Analyst Ratings

SPRYNASDAQ
Logo brought to you by Benzinga Data
$10.20
-0.03-0.29%
At close: -
$10.24
0.040.39%
After Hours: 7:58 PM EDT
Consensus Rating1
Outperform
Highest Price Target1
$30.00
Lowest Price Target1
$14.00
Consensus Price Target1
$23.60

ARS Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:SPRY | Benzinga

ARS Pharmaceuticals Inc has a consensus price target of $23.6 based on the ratings of 6 analysts. The high is $30 issued by Cantor Fitzgerald on October 8, 2024. The low is $14 issued by SVB Leerink on December 13, 2022. The 3 most-recent analyst ratings were released by Raymond James, Leerink Partners, and Cantor Fitzgerald on January 14, 2025, January 13, 2025, and October 8, 2024, respectively. With an average price target of $28.33 between Raymond James, Leerink Partners, and Cantor Fitzgerald, there's an implied 176.69% upside for ARS Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
3
Sep 24
1
Oct 24
2
Jan
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.7
Strong Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Raymond James
Leerink Partners
Cantor Fitzgerald
Wedbush
SVB Leerink

1calculated from analyst ratings

Analyst Ratings for ARS Pharmaceuticals

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for ARS Pharmaceuticals (SPRY) stock?

A

The latest price target for ARS Pharmaceuticals (NASDAQ:SPRY) was reported by Raymond James on January 14, 2025. The analyst firm set a price target for $28.00 expecting SPRY to rise to within 12 months (a possible 173.44% upside). 11 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for ARS Pharmaceuticals (SPRY)?

A

The latest analyst rating for ARS Pharmaceuticals (NASDAQ:SPRY) was provided by Raymond James, and ARS Pharmaceuticals maintained their strong buy rating.

Q

When was the last upgrade for ARS Pharmaceuticals (SPRY)?

A

The last upgrade for ARS Pharmaceuticals Inc happened on August 13, 2024 when Raymond James raised their price target to $22. Raymond James previously had an outperform for ARS Pharmaceuticals Inc.

Q

When was the last downgrade for ARS Pharmaceuticals (SPRY)?

A

The last downgrade for ARS Pharmaceuticals Inc happened on September 20, 2023 when William Blair changed their price target from N/A to N/A for ARS Pharmaceuticals Inc.

Q

When is the next analyst rating going to be posted or updated for ARS Pharmaceuticals (SPRY)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ARS Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ARS Pharmaceuticals was filed on January 14, 2025 so you should expect the next rating to be made available sometime around January 14, 2026.

Q

Is the Analyst Rating ARS Pharmaceuticals (SPRY) correct?

A

While ratings are subjective and will change, the latest ARS Pharmaceuticals (SPRY) rating was a maintained with a price target of $26.00 to $28.00. The current price ARS Pharmaceuticals (SPRY) is trading at is $10.24, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch